BriaCell Therapeutics Corp. (NASDAQ:BCTX) Short Interest Down 30.7% in December

BriaCell Therapeutics Corp. (NASDAQ:BCTX) was the target of a large decrease in short interest during the month of December. As of December 31st, there was short interest totalling 1,650,000 shares, a decrease of 30.7% from the December 15th total of 2,380,000 shares. Approximately 4.2% of the shares of the stock are short sold. Based on an average daily volume of 1,540,000 shares, the days-to-cover ratio is presently 1.1 days.

Hedge Funds Weigh In On BriaCell Therapeutics

A hedge fund recently bought a new stake in BriaCell Therapeutics stock. Vontobel Holding Ltd. bought a new stake in shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 80,000 shares of the company’s stock, valued at approximately $99,000. Vontobel Holding Ltd. owned 0.44% of BriaCell Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 15.42% of the company’s stock.

BriaCell Therapeutics Stock Down 3.7 %

BCTX stock traded down $0.01 during midday trading on Thursday, reaching $0.39. 400,253 shares of the company’s stock traded hands, compared to its average volume of 1,180,545. The company has a 50-day simple moving average of $0.68 and a two-hundred day simple moving average of $0.75. BriaCell Therapeutics has a 1-year low of $0.37 and a 1-year high of $4.61. The company has a market cap of $17.02 million, a price-to-earnings ratio of -0.43 and a beta of 1.55.

Shares of BriaCell Therapeutics are scheduled to reverse split on the morning of Wednesday, January 29th. The 1-15 reverse split was announced on Friday, January 3rd. The number of shares owned by shareholders will be adjusted after the closing bell on Tuesday, January 28th.

BriaCell Therapeutics (NASDAQ:BCTX) last issued its quarterly earnings results on Monday, December 16th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). Equities research analysts forecast that BriaCell Therapeutics will post -1.01 EPS for the current year.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of BriaCell Therapeutics in a research report on Thursday, December 12th.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.